Share Twitter LinkedIn Facebook Email Jens Hillengass MD @JHillengass Of Roswell Park Comprehensive Cancer Center Discusses Updates In Myeloma: Bispecific Antibodies & New Treatment Coming For Multiple Myeloma That Was Used In POEMS Syndrome.
53 vs 31 Month Isatuximab-VRD Results: My Interview with SANOFI’s Global Product Head at ASCO 2024 ASCO Annual Meeting 2 Mins Read